NASDAQ:APRI - Apricus Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.48 +0.13 (+37.14 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$0.35
Today's Range$0.32 - $0.50
52-Week Range$0.25 - $3.34
Volume3.42 million shs
Average Volume1.28 million shs
Market Capitalization$8.53 million
P/E Ratio-0.48
Dividend YieldN/A
Apricus Biosciences logoApricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

Receive APRI News and Ratings via Email

Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.50
Quick Ratio3.50


Trailing P/E Ratio-0.48
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.76 million
Price / Sales1.95
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book1.66


EPS (Most Recent Fiscal Year)($0.99)
Net Income$320,000.00
Net MarginsN/A
Return on Equity-193.26%
Return on Assets-137.09%


Outstanding Shares23,440,000

Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences Inc (NASDAQ:APRI) posted its earnings results on Thursday, May, 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. View Apricus Biosciences' Earnings History.

What price target have analysts set for APRI?

1 brokers have issued 12-month price objectives for Apricus Biosciences' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' share price to reach $1.00 in the next twelve months. View Analyst Ratings for Apricus Biosciences.

Who are some of Apricus Biosciences' key competitors?

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the folowing people:
  • Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 54)
  • Mr. Brian T. Dorsey, Sr. VP & Chief Devel. Officer (Age 49)
  • Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 42)
  • Ms. Kelly Deck, Exec. Director of Fin.
  • Ms. Mary Naggs, VP and Gen. Counsel

Has Apricus Biosciences been receiving favorable news coverage?

Headlines about APRI stock have trended positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apricus Biosciences earned a news impact score of 0.27 on Accern's scale. They also gave press coverage about the company an impact score of 44.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Apricus Biosciences' major shareholders?

Apricus Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (7.68%), SABBY MANAGEMENT, LLC (7.68%) and SABBY MANAGEMENT, LLC (7.68%). View Institutional Ownership Trends for Apricus Biosciences.

Which institutional investors are buying Apricus Biosciences stock?

APRI stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Apricus Biosciences.

How do I buy shares of Apricus Biosciences?

Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apricus Biosciences' stock price today?

One share of APRI stock can currently be purchased for approximately $0.48.

How big of a company is Apricus Biosciences?

Apricus Biosciences has a market capitalization of $8.53 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.

How can I contact Apricus Biosciences?

Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]

MarketBeat Community Rating for Apricus Biosciences (APRI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.